-
Mashup Score: 46
A suboptimal prostate-specific antigen (PSA) response to neoadjuvant androgen deprivation therapy (ADT) among men who go on to receive definitive radiotherapy for prostate cancer might suggest the existence of castration-resistant disease or altered androgen receptor (AR) signaling. This in turn may portend worse long-term clinical outcomes, especially in men with high-risk disease. We set out to evaluate the prognostic impact of poor PSA response to neoadjuvant ADT in men with high-risk prostate cancer.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase III Randomized Controlled Trial - 1 year(s) ago
Pelvic radiotherapy may lead to decreased bone mineral density (BMD) and increased risk of fracture which could be of particular concern in prostate cancer (PCa) patients who also receive androgen deprivation therapy (ADT). We performed exploratory analysis of a randomized, double-blind, placebo-controlled trial to determine if exposure to prior pelvic external beam radiotherapy (XRT) affects BMD and risk of fracture in PCa patients treated with ADT.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
RT @SouMyajiT_RO: https://t.co/U0QzQKHpew Happy to share our in-press article @IJROBP @ASTRO_org. In this 2ndary analysis of a phase III RC…
-
-
Mashup Score: 5Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase III Randomized Controlled Trial - 1 year(s) ago
Pelvic radiotherapy may lead to decreased bone mineral density (BMD) and increased risk of fracture which could be of particular concern in prostate cancer (PCa) patients who also receive androgen deprivation therapy (ADT). We performed exploratory analysis of a randomized, double-blind, placebo-controlled trial to determine if exposure to prior pelvic external beam radiotherapy (XRT) affects BMD and risk of fracture in PCa patients treated with ADT.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
RT @SouMyajiT_RO: https://t.co/U0QzQKHpew Happy to share our in-press article @IJROBP @ASTRO_org. In this 2ndary analysis of a phase III RC…
-
-
Mashup Score: 4
The trigone exhibits little volume change, but considerable interfractional displacement/deformation. As a result, the relative volume of the trigone receiving high doses during prostate SBRT varies substantially between fractions, which could influence GU toxicity and may not be predicted by radiat …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@DrAndrewLoblaw @alison_tree @dr_vesi https://t.co/rBbNwjvPSn 0 PTV margin is bold!
-
-
Mashup Score: 4Urethral Interfractional Geometric and Dosimetric Variations of Prostate Cancer Patients: A Study Using an Onboard MRI - PubMed - 1 year(s) ago
Urethral interfractional motion and anatomic change can result in daily treatment violating urethral constraints. Onboard MRI with good visualization of the prostatic urethra can be a valuable tool to help better protect the urethra through patient setup or online adaptive RT.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@alison_tree Urethral dose is harder; we were not able to see it routinely. We did a small analysis on 26 patients who had a custom urethral detection sequence taken after the final fraction of SBRT https://t.co/kZJKIPKALQ.
-
-
Mashup Score: 64
Emerging data suggest that trigone dosimetry may be more associated with post-stereotactic body radiotherapy (SBRT) urinary toxicity than whole bladder dosimetry. Herein, we quantify the dosimetric impact of interfractional displacement and deformation of the whole bladder and trigone during prostate SBRT using on-board, pre-treatment 0.35T MRI images.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
Great work led by @bethneilsen out in @IJROBP looking at the dosimetric impact of trigone/bladder displacements and toxicity in the MIRAGE trial https://t.co/t8WfQL09Hk
-
-
Mashup Score: 0
This cohort study assesses prostate cancer–specific mortality and distant metastasis outcomes among men with high-risk prostate cancer treated with radical prostatectomy or external beam radiotherapy with or without brachytherapy boost.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet-
@DrAndrewLoblaw @dr_coops That would seem to be a large limitation when survival-based endpoints are being tracked. Particularly in our large high-risk consortium paper (which had a urologist senior author! @Tilki_De ) https://t.co/0Qh3IHnzzj we certainly accounted for "optimal" treatment.
-
-
Mashup Score: 0
Randomised trials have investigated various androgen deprivation therapy (ADT) intensification strategies in men receiving radiotherapy for the treatm…
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
@DrAndrewLoblaw @dr_coops We know from MARCAP https://t.co/4Ss9OQVcox that there is a large survival benefit to (a) adding ADT and (b) prolonging ADT. We know from SANDSTORM https://t.co/gZRVcpAnNx that ADT sequencing has a major impact too
-
-
Mashup Score: 3Bullseye or Tip of the Iceberg: Magnetic Resonance Imaging–visible Disease in Radiorecurrent Prostate Cancer - 1 year(s) ago
Author links open overlay panel Amar U. Kishan a b, Luca F. Valle a c, Leonard S. Marks b There are more references available in the full text version of this
Source: www.sciencedirect.comCategories: General Medicine News, Hem/OncsTweet-
Great work on the importance of appropriate biopsy technique in radiorecurrent disease. Honored to write the corresponding editorial in @EUplatinum https://t.co/Q8hEMT6zf2 with Luca Valle and Lenny Marks @UCLAJCCC @abhiAsolanki @ndesai2005 @VedangMurthy https://t.co/fhQ240tWje
-
-
Mashup Score: 2
World Journal of Urology – The synergy of combining androgen receptor-signaling inhibition (ARSI) to radiotherapy (RT) in prostate cancer has been largely attributed to non-homologous end joining…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet-
@DrSpratticus @UMichRadOnc Great work, here is the in press link https://t.co/h2xbLdZwFt
-
Proud of my team @UCLAJCCC radiation oncology for having two papers in press @IJROBP right at the close of 2023! https://t.co/CIrVdCnXB4 https://t.co/1yRib3aVX9